Novo Nordisk predicts period of "different" growth when semaglutide patents expire

The pharmaceutical company's growth profile will change when patents concerning the GLP-1 molecule semaglutide run out, says CEO at Novo Nordisk Lars Fruergaard Jørgensen.

by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

When patents related to Novo Nordisk's bestselling GLP-1 molecule, semaglutide, expire, it might affect the company's growth, CEO at Novo Nordisk Lars Fruergaard Jørgensen tells Danish business daily Børsen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

High growth at low margins is better than the reverse, says Novo Nordisk CEO
For subscribers
Novo CEO is on the hunt for future growth: "The pressure is bigger than ever"
For subscribers
Year-to-date obesity drug sales at Novo Nordisk surpass all of 2020
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

EU Health Commissioner Stella Kyriakides has received an open letter from trade association Medtech Europe and 34 national organizations. | Foto: Julien Warnand/AP/Ritzau Scanpix

Other

European trade association calls for comprehensive reform of MDR and IVDR

Medtech Europe considers EU regulations to be unpredictable, complex and slow.

For subscribers

Pharma & biotech

Kåre Schultz: Former chairman of Novo Nordisk Foundation cost me the job as Novo Nordisk CEO

For subscribers

Søren Nielsen, CEO of hearing aid company Demant. | Foto: Demant / Pr

Hearing health

Jyske Bank questions Demant's continued momentum

For subscribers

Foto: Jim Vondruska/Reuters/Ritzau Scanpix

Pharma & biotech

Third time's the charm: Novo Nordisk makes new bid to get obesity drug reimbursed in Danish home market

For subscribers

Novo Nordisk Foundation's investment company, Novo Holdings, together with Gurnet Point Capital, has completed the acquisition of the US biotech company Paratek for USD 462 million including debt corresponding to DKK 3.2 billion. | Foto: Novo Holdings / Pr

Pharma & biotech

Novo Holdings completes acquisition of US antibiotics company for DKK 3.2bn

For subscribers

Pharma & biotech

Leo acquisition negotiated with four suitors while struggling to survive

For subscribers

Jefferies on Novo Nordisk: Little risk of semaglutide patent dispute - but could raise concerns
The actual risk of competition from generic drugs is limited, according to Jefferies analyst, although pharmaceutical company Viatris is challenging patents related to Novo Nordisk’s semaglutide.
For subscribers
Media: Issues at Novo Nordisk factory have been known for more than a year
Already in May of last year, the FDA released a report documenting quality control failures at Novo Nordisk’s factory in Clayton, USA, Reuters reports. (Updated)
For subscribers
Novo Nordisk and UNICEF extend joint initiative to combat childhood obesity
As part of the extended agreement, Novo Nordisk will invest USD 8m over the next three years.
For subscribers
Board member appointed as new CEO of Orphazyme
The biotech company prepares new activities.
For subscribers
Eli Lilly sues clinics for selling fake diabetes drug
Novo Nordisk was also out in force in June.
For subscribers
Media: This is why the FDA has reprimanded Novo Nordisk following US plant inspection
Inadequate oversight of batch deviations and messy microbial controls are the cause of an FDA Form 483 for a Novo Nordisk plant in the US, reports media outlet Fierce Pharma.
For subscribers

Kåre Schultz: Former chairman of Novo Nordisk Foundation cost me the job as Novo Nordisk CEO

The former chairman of the Novo Nordisk Foundation, Sten Scheibye, however, says that he does not recognize this interpretation.

For subscribers

Pharma & biotech

After two years of losses Leo Pharma is on track to profitability

The pharmaceutical company is on track to deliver on the big goal: to become profitable by 2023.

For subscribers

Other

European trade association calls for comprehensive reform of MDR and IVDR

Medtech Europe considers EU regulations to be unpredictable, complex and slow.

For subscribers

Novo Nordisk's manufacturing facility in Clayton, the US. | Photo: Novo Nordisk/pr

Pharma & biotech

Novo Nordisk facility in the US allegedly receives FDA notice

The FDA has reportedly notified the company’s management of problematic conditions.

For subscribers

Hearing health

Jyske Bank questions Demant's continued momentum

With increasing competition in the hearing aid market, Jyske Bank analyst Janne Vincent Kjær does not expect Demant to continue its strong momentum into 2024.

For subscribers